Trial Profile
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Niacin (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Pharmacodynamics
- 23 May 2013 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
- 22 May 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 23 May 2012 Planned End Date changed from 1 Feb 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.